LLY

Eli Lilly to supply U.S. 300,000 vials of potential COVID-19 drug

Credit: REUTERS/VINCENT KESSLER

Eli Lilly and Co said on Wednesday it signed an agreement with the U.S. government to supply 300,000 vials of its experimental antibody drug to treat COVID-19 for $375 million.

Adds details on agreement

Oct 28 (Reuters) - Eli Lilly and Co LLY.N said on Wednesday it signed an agreement with the U.S. government to supply 300,000 vials of its experimental antibody drug to treat COVID-19 for $375 million.

The agreement is for delivery over the two months following an emergency use authorization if granted by U.S. regulators. The U.S. government also has the provision to purchase up to an additional 650,000 vials through June 30, 2021, the company said.

The company submitted a request to the U.S. Food and Drug Administration in October for emergency use authorization of the drug for treating mild to moderate COVID-19 patients.

The U.S. government has committed that patients will have no out-of-pocket costs for the medicine, although healthcare facilities may charge a fee for the product's administration, Lilly said.

(Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb Chakrabarty)

((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manasmishra24; within U.S. +1 646 223 8780, outside U.S. +91 806749 2709;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

LLY

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More